Meibomian gland disease and reimbursement – Ophthalmology Management

Treatment of meibomian gland dysfunction (MGD) is garnering increased interest, but you need to consider reimbursement issues.

This article answers the following questions:

  • What treatments are available for MGD?
  • What documentation is required to support treatment?
  • How is this treatment reimbursed?
  • What CPT code applies: 67700 or 0207T?
  • What is meibomian gland dysfunction?

This article was published in Ophthalmology Management’s Coding & Reimbursement column, which is written by Corcoran’s Executive Vice-President, Suzanne Corcoran, COE. To view the entire article in Ophthalmology Management, click on the link below:

Related Posts

Website by MIC